Table 2.

Uremic toxin levels over time: Intention-to-treat participants

TimeSerum IS, mg/dlUrine IS, mg/dlβ2-MG, mg/L
ControlΔ (95% CI)AST-120Δ (95% CI)ControlΔ (95% CI)AST-120Δ (95% CI)ControlΔ (95% CI)AST-120Δ (95% CI)
Enrollment0.70±0.05NA0.64±0.03NA7.71±0.486.70±0.326.91±0.166.64±0.15
12 mo0.89±0.050.18 (−1.61 to 1.90)0.71±0.050.11 (−1.34 to 1.95)7.14±0.37−0.82 (−25.53 to 13.72)4.82±0.03−1.81 (−14.64 to 10.52)7.63±0.271.19 (−2.91 to 8.37)7.94±0.261.58 (−2.50 to 10.07)
24 mo1.03±0.070.29 (−1.23 to 2.41)0.65±0.050.12 (−1.15 to 1.95)7.90±0.400.17 (−24.97 to 15.38)5.22±0.36−1.17 (−12.69 to 10.59)7.23±0.260.96 (−3.89 to 8.13)7.39±0.291.35 (−2.14 to 9.33)
36 mo0.98±0.080.26 (−1.51 to 2.95)0.58±0.040.07 (−1.26 to 1.59)8.51±0.610.45 (−26.35 to 21.35)5.50±0.58−1.01 (−15.80 to 17.06)7.16±0.281.17 (−3.77 to 6.95)6.57±0.231.07 (−2.48 to 5.48)
P value (randomization)<0.001<0.0010.58
P value (time)<0.0010.04<0.001
P value (randomization × time)0.290.760.25
  • IS, indoxyl sulfate; β2-MG, β2-microglobulin; 95% CI, 95% confidence interval; NA, not applicable.